<DOC>
	<DOCNO>NCT00639691</DOCNO>
	<brief_summary>This study objective provide compassionate use access omalizumab ( Xolair ) evaluate Safety Xolair subject severe allergic asthma remain symptomatic despite optimal therapy accord GINA step 4 treatment guideline .</brief_summary>
	<brief_title>A Compassionate Access Protocol Assess Safety XolairTM ( Omalizumab ) Patients ( ≥ 6 Years Old ) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>male female , ≥ 6years age ; diagnosis allergic asthma ≥ 1 year duration accord American Thoracic Society ( ATS ) criterion ; severe persistent allergic asthma remain symptomatic despite optimal therapy ( per Canadian Asthma Consensus Report ( 1999 ) ) ; Subjects successfully complete one follow protocol : CIGE025A011E3 , CIGE025A2425 , CIGE025AIA05 ; elevate immunoglobin E level significant systemic disease pregnancy lactation active lung disease allergic asthma ( eg : cystic fibrosis , bronchiestasis ) ; history food drug relate severe anaphylactoid anaphylactic reaction ( ) ; current treatment warfarin ( Coumadin® ) , immunomodulatory therapy ( e.g. , methotrexate , gold , cyclosporine ) , antiplatelet therapy .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Asthma , Anti-immunoglobin E , omalizumab</keyword>
</DOC>